RenovoRx Inc
Research RenovoRx Inc (RNXT) on Bullrun: market cap USD 64.07M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRNXT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 64.07M
- Financial periodQ1 2026
- RevenueUSD 563.00K
- Net income-USD 3.52M
- Free cash flow-USD 3.71M
- Gross margin85.1%
Valuation Snapshot
latest market cap is USD 64.07M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.12M | -USD 11.17M | -USD 10.98M | 70.9% | -0.32 | USD 7.02M | USD 212.00K | USD 5.42M |
| FY2024 | USD 43.00K | -USD 8.81M | -USD 9.14M | 100.0% | -0.4 | USD 7.15M | USD 278.00K | USD 4.48M |
| FY2023 | n/a | -USD 10.23M | n/a | n/a | -0.99 | USD 1.17M | USD 0 | USD 3.00M |
| FY2022 | n/a | -USD 9.89M | n/a | n/a | -1.09 | USD 4.39M | n/a | USD 6.16M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 64.07M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 30.76M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 31.00M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 24.49M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 21.38M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 43.24M | n/a | n/a | n/a |
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is RenovoRx Inc's market cap?
RenovoRx Inc's market capitalization is USD 64.07M.
What does RenovoRx Inc do?
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.